The Flexor Advantage: Tuning In Vivo Performance via Advanced Delivery Architecture
If your drug candidate shows promising in vitro release but fails in vivo, the culprit is often not the molecule—it is the delivery architecture. Many...
5 articles in this category
If your drug candidate shows promising in vitro release but fails in vivo, the culprit is often not the molecule—it is the delivery architecture. Many...
This comprehensive guide explores how to treat the delivery system as an active variable in tuning release kinetics for complex active pharmaceutical ...
For teams working on advanced drug delivery, the central challenge has shifted from whether a carrier can encapsulate a payload to how precisely it ca...
The Strategic Imperative: Why Convergence is the New BaselineFor teams developing next-generation therapies, the old paradigm of separate development ...
Introduction: The Static Problem and the Dynamic SolutionFor years, controlled release has been a game of averages. Formulations were designed to deli...